Contact
searchSearch
HMP Global

Q&As

Monica Schwartzman
Q&A
Monica Schwartzman, MD, on Medication Preferences Among Patients With PsA
08/21/2023
Dr Schwartzman answered our questions about her recent study of what patients with psoriatic arthritis want most from their medical therapy.
Dr Schwartzman answered our questions about her recent study of what patients with psoriatic arthritis want most from their medical therapy.
Dr Schwartzman answered our...
08/21/2023
Rheumatology & Arthritis
Alexis Ogdie
Q&A
Alexis Ogdie, MD, on a Treat To Target Approach to Psoriatic Arthritis
06/29/2022
How beneficial is achieving minimal disease activity for patients with psoriatic arthritis? Alexis Ogdie, MD, of the University of Pennsylvania, answers some questions about her research into this subject in this Q&A.
How beneficial is achieving minimal disease activity for patients with psoriatic arthritis? Alexis Ogdie, MD, of the University of Pennsylvania, answers some questions about her research into this subject in this Q&A.
How beneficial is achieving...
06/29/2022
Rheumatology & Arthritis
Joshua Baker, MD
Q&As
Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
04/21/2022
Joshua Baker, MD, from the Perelman School of Medicine at the University of Pennsylvania, answers our questions about his recent study into potential links between body mass, obesity, and the risk of death among patients with rheumatoid...
Joshua Baker, MD, from the Perelman School of Medicine at the University of Pennsylvania, answers our questions about his recent study into potential links between body mass, obesity, and the risk of death among patients with rheumatoid...
Joshua Baker, MD, from the...
04/21/2022
Rheumatology & Arthritis
Lianne Gensler
Q&A
Bimekizumab Therapy and Beyond for Ankylosing Spondylitis
02/01/2022
Lianne Gensler, MD, rheumatologist and director of the University of California, San Francisco, Spondyloarthritis Clinic, discussed the role of IL-17 in ankylosing spondylitis (AS) and the use of bimekizumab in treating this disease.
Lianne Gensler, MD, rheumatologist and director of the University of California, San Francisco, Spondyloarthritis Clinic, discussed the role of IL-17 in ankylosing spondylitis (AS) and the use of bimekizumab in treating this disease.
Lianne Gensler, MD,...
02/01/2022
Autoimmune
Celia Mead, Executive Director of BIRD
Q&As
Bath Institute for Rheumatic Diseases: Empowering Psoriatic Arthritis Researchers and Patients Alike
01/11/2022
Celia Mead, executive director of BIRD, spoke about the organization's initiatives for psoriatic arthritis and other diseases after receiving the UPLIFT Innovation Challenge grant.
Celia Mead, executive director of BIRD, spoke about the organization's initiatives for psoriatic arthritis and other diseases after receiving the UPLIFT Innovation Challenge grant.
Celia Mead, executive director...
01/11/2022
The Dermatologist
Q&As
Dr Joan Merrill: Insights on Anifrolumab
07/12/2021
Joan T. Merrill, MD, discusses her insights into anifrolumab and its benefits in treating moderate to severe systemic lupus erythematosus (SLE).
Joan T. Merrill, MD, discusses her insights into anifrolumab and its benefits in treating moderate to severe systemic lupus erythematosus (SLE).
Joan T. Merrill, MD, discusses...
07/12/2021
The Dermatologist
Jason Schairer, MD, on Dermatologic Manifestations in IBD
Q&As
Jason Schairer, MD, on Dermatologic Manifestations in IBD
06/06/2021
In this Q&A, Dr Schairer answers our questions about the presentation, diagnosis, and treatment of dermatological conditions among patients with inflammatory bowel disease.
In this Q&A, Dr Schairer answers our questions about the presentation, diagnosis, and treatment of dermatological conditions among patients with inflammatory bowel disease.
In this Q&A, Dr Schairer answers...
06/06/2021
Autoimmune
Dr Peter Lio on the Relationship Between AD and IMIDs
Q&As
Dr Peter Lio on the Relationship Between AD and IMIDs
04/16/2021
At the Interdisciplinary Autoimmune Summit 2021, Dr Lio spoke about emerging therapies for moderate to severe AD. In an interview with ALN, he answered several questions regarding advanced management of the disease.
At the Interdisciplinary Autoimmune Summit 2021, Dr Lio spoke about emerging therapies for moderate to severe AD. In an interview with ALN, he answered several questions regarding advanced management of the disease.
At the Interdisciplinary...
04/16/2021
The Dermatologist
Computer
Q&As
Q&A: Impact of COVID-19 on Patients With Psoriatic Arthritis
03/04/2021
Joseph F. Merola, MD, MMSc discussed the impact of the COVID-19 pandemic among patients with psoriatic arthritis.
Joseph F. Merola, MD, MMSc discussed the impact of the COVID-19 pandemic among patients with psoriatic arthritis.
Joseph F. Merola, MD, MMSc...
03/04/2021
Autoimmune
Thomas Werfel, MD, on the Safety of Tralokinumab for the Treatment of Atopic Dermatitis
Q&As
Thomas Werfel, MD, on the Safety of Tralokinumab for the Treatment of Atopic Dermatitis
02/11/2021
In this Q&A, Thomas Werfel, MD, discussed findings from pooled analyses that investigated the safety of tralokinumab among patients with atopic dermatitis.
In this Q&A, Thomas Werfel, MD, discussed findings from pooled analyses that investigated the safety of tralokinumab among patients with atopic dermatitis.
In this Q&A, Thomas Werfel, MD,...
02/11/2021
Autoimmune

Popular Articles

News
Lupus: Predictors of Poor Outcomes Following Hydroxychloroquine Tapering, Discontinuation Are Identified
01/14/2021
Researchers have determined that several demographic and clinical factors are associated with poor outcomes after hydroxychloroquine tapering or discontinuation. Find out what these factors are.
Researchers have determined that several demographic and clinical factors are associated with poor outcomes after hydroxychloroquine tapering or discontinuation. Find out what these factors are.
Researchers have determined that...
01/14/2021
Autoimmune
News
How Common Are Musculoskeletal Manifestations Among Patients With IBD Receiving Vedolizumab?
11/13/2020
The researchers determined the percentage of patients with musculoskeletal manifestations and whether those manifestations were mechanical or inflammatory.
The researchers determined the percentage of patients with musculoskeletal manifestations and whether those manifestations were mechanical or inflammatory.
The researchers determined the...
11/13/2020
Autoimmune
News
Risk of Serious Infection, Glucocorticoid Use Are Linked Among Patients With RA
09/29/2020
While low-dose glucocorticoids are commonly used in the management of rheumatoid arthritis, the safety of the medications’ long-term use is unclear. Researchers evaluated the association between long-term low-dose glucocorticoid use and risk...
While low-dose glucocorticoids are commonly used in the management of rheumatoid arthritis, the safety of the medications’ long-term use is unclear. Researchers evaluated the association between long-term low-dose glucocorticoid use and risk...
While low-dose glucocorticoids...
09/29/2020
Autoimmune
Poll
Pop Quiz: Autoimmune Protocol Diet
08/13/2020
A few studies have assessed the efficacy of the autoimmune protocol diet among patients with inflammatory bowel disease and Hashimoto thyroiditis. This anti-inflammatory diet is very restrictive. Which of the following foods are allowed on...
A few studies have assessed the efficacy of the autoimmune protocol diet among patients with inflammatory bowel disease and Hashimoto thyroiditis. This anti-inflammatory diet is very restrictive. Which of the following foods are allowed on...
A few studies have assessed the...
08/13/2020
Autoimmune
Exclusive Preview: Biosimilars for IMIDs: Availability, Affordability, and Interchangeability
Conference Coverage
Exclusive Preview: Biosimilars for IMIDs: Availability, Affordability, and Interchangeability
07/10/2020
In this short video from IAS 2020, Jonathan Kay, MD, summarizes why biosimilar use may be limited in the United States in his presentation, "Biosimilars for IMIDs: Availability, Affordability, and Interchangeability."
In this short video from IAS 2020, Jonathan Kay, MD, summarizes why biosimilar use may be limited in the United States in his presentation, "Biosimilars for IMIDs: Availability, Affordability, and Interchangeability."
In this short video from IAS...
07/10/2020
Autoimmune

Stay In the Know

Autoimmune Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use